Combined chemo-immunotherapy as a prospective strategy to combat cancer: A nanoparticle based approach

Molecular Pharmaceutics

Volumn 7, Issue 5, 2010, Pages 1778-1788

  Roy, Aniruddha ^a   Singh, Manu Smriti ^a   Upadhyay, Pramod ^a   Bhaskar, Sangeeta ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Chemo immunotherapy; immunostimulation; nanoparticles; paclitaxel; PLGA; SPLPS; tumor targeting

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; NANOPARTICLE; PACLITAXEL; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; ENCAPSULATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SALMONELLA ENTERICA; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; IMMUNOTHERAPY; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOCAPSULES; PACLITAXEL;

EID: 77957732045     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100153r     Document Type: Article

References (39)

1. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents VI. The isolation and structure of taxol: a novel anti leukemic and antitumour agent from Taxus brevifolia J. Am. Chem. Soc. 1971, 93, 2325-2327
2. Schiff, P. B.; Fant, J.; Horowitz, S. B. Promotion of microtubule assembly in vitro by taxol Nature 1979, 227, 665-667
3. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A.; Cremophor, E. L. the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 2001, 37, 1590-1598
4. Tarr, B. D.; Yalkowsky, S. H. A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs J. Parenter. Sci. Technol. 1987, 41, 31-33
5. Sparreboom, A.; Tellingen, O. V.; Nooijen, W. J.; Beijnen, J. H. Tissue distribution, metabolism and excretion of paclitaxel in mice Anticancer Drugs 1996, 7, 78-86
6. Eiseman, J. L.; Eddington, N. D.; Leslie, J.; MacAuley, C.; Sentz, D. L.; Egorin, M. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice Cancer Chemother. Pharmacol. 1994, 34, 465-471
7. Li, C.; Yu, D. F.; Inoue, T.; Yang, D. J.; Milas, L.; Hunter, N. R.; Kim, E. E.; Wallace, S. Indium labeled paclitaxel: synthesis, biodistribution and imaging property of In-DTPA-paclitaxel in mice bearing mammary tumor J. Nucl. Med. 1997, 38, 1042-1047
8. Hennenfent, K. L.; Govindan, R. Novel formulations of taxanes: a review. Old wine in a new bottle Ann. Oncol. 2006, 17, 735-749
9. Kim, R.; Emi, M.; Tanabe, K.; Arihiro, K. Tumor-driven evolution of immunosuppressive networks during malignant progression Cancer Res. 2006, 66, 5527-5536
10. Van der Most, R. G.; Nowak, A. K.; Lake, R. A. Immune Stimulatory Features of Classical Chemotherapy. In Cancer Immunotherapy: Immune suppression and tumor growth; Prendergast, G. C.; Elizabeth, M. J., Eds.; Academic Press: New York, 2007; pp 235 - 256.
11. Yoshinori, N.; Noriyuki, H.; Yoshimitsu, M.; Chikage, I.; Kunihiro, Y.; Tomoko, T.; Katsuhiro, T. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface Anticancer Res. 2000, 20, 3293-3299
12. Emens, L. A.; Jaffe, E. M. Immunotherapy and Cancer Therapeutics: Why Partner ? In Cancer Immunotherapy: Immune suppression and tumor growth; Prendergast, G. C.; Elizabeth, M. J., Eds.; Academic Press: New York, 2007; pp 207 - 233.
13. Lundin, J. I.; Checkoway, H. Endotoxin and cancer Environ. Health Perspect. 2009, 117, 1344-1350
14. Onier, N.; Hilpert, S.; Arnould, L.; Saint-Giorgio, V.; Davies, G.; Bauer, J.; Jeannin, J. F. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats Clin. Exp. Metastasis 1999, 17, 299-306
15. Yang, D.; Satoh, M.; Ueda, H.; Tsukagoshi, S.; Yamazaki, M. Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects Cancer Immunol. Immunother. 1994, 38, 287-293
16. Evans, J. T.; Cluff, C. W.; Johnson, D. A.; Lacy, M. J.; Persing, D. H.; Baldridge, J. R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529 Expert Rev. Vaccines 2003, 2, 219-229
17. Hamdy, S.; Haddadi, A.; Somayaji, V.; Ruan, D.; Samuel, J. Pharmaceutical analysis of synthetic lipid A-based vaccine adjuvants in poly(d,l-lactic-co- glycolic acid) nanoparticle formulations J. Pharm. Biomed. 2007, 44, 914-23
18. McIntire, F. C.; Hargie, M. P.; Schenck, J. R.; Finley, R. A.; Sievert, H. W.; Rietschel, E. T.; Rosenstreich, D. L. Biological properties of nontoxic derivatives of a lipopolysaccahride from Escherichia coli K235 J. Immunol. 1976, 117, 674-678
19. Koziara, M. K.; Whisman, T. R.; Tseng, M. T.; Mumper, R. J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors J. Controlled Release 2006, 112, 312-319
20. Danhier, F.; Lecouturier, N.; Vroman, B.; Jerome, C.; Marchand-Brynaert, J.; Feron, O.; Preat, V. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation J. Controlled Release 2009, 133, 11-17
21. Feng, S. S.; Mu, L.; Win, K. Y.; Huang, G. F. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel Curr. Med. Chem. 2004, 11, 413-24
22. Brannon-Pepas, L.; Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy Adv. Drug Delivery Rev. 2004, 56, 1649-1659
23. Katare, Y. K.; Muthukumaran, T.; Panda, A. K. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles Int. J. Pharm. 2005, 301, 149-160
24. Raymond, E.; Hanauske, A.; Faivre, S. Effects of prolonged versus short-term exposure paclitaxel (taxol) on human tumor colony forming units Anti-Cancer Drugs 1997, 84, 379-385
25. Fonseca, C.; Simões, S.; Gaspar, R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity J. Controlled Release 2002, 83, 273-286
26. Milross, C. G.; Mason, K. A.; Hunter, N. R.; Chung, W.-K.; Peters, L. J.; Milas, L. Relationship of Mitotic Arrest and Apoptosis to Antitumor Effect of Paclitaxel J. Natl. Cancer Inst. 1996, 88, 1308-1314
27. Muta, T.; Takeshige, K. Essential roles of CD14 and lipopolysaccharide- binding protein for activation of toll-like receptor (TLR)2 as well as TLR4 Reconstitution of TLR2- and TLR4-activation by distinguishable ligands in LPS preparations Eur. J. Biochem. 2001, 268, 4580-4589
28. Qin, M. F.; Wu, X. Z.; Zhang, W. Z. The study of LPS-induced TNF cytotoxicity and the influential factors in vitro Chinese J. Clin. Oncol. 1995, 22, 776-779
29. Mehrotra, P. T.; Grant, A. J.; Siegel, J. P. Synergistic effects of IL-7 and IL-12 on human T cell activation J. Immunol. 1995, 154, 5093-5102
30. Hoag, K. A.; Lipscomb, M. F.; Izzo, A. A.; Street, N. E. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice Am. J. Respir. Cell Mol. Biol. 1997, 17, 733-739
31. Fiorentino, D. F.; Zlotnik, A.; Vieira, P.; Mosmann, T. R.; Howard, M.; Moore, K. W.; O'Garra, A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells J. Immunol. 1991, 146, 3444-3451
32. Sahooa, S K.; Panyama, J.; Prabhaa, S.; Labhasetwar, V. Residual polyvinyl alcohol associated with poly(D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake J. Controlled Release 2002, 82, 105-114
33. Javeed, A.; Ashraf, M.; Riaz, A.; Ghafoor, A.; Afzal, S.; Mukhtar, M. M. Paclitaxel and immune system Eur. J. Pharm. Sci. 2009, 38, 283-290
34. Tsuda, N.; Chang, D. Z.; Mine, T.; Efferson, C.; Garciá-Sastre, A.; Wang, X.; Ferrone, S.; Ioannides, C. G. Taxol Increases the Amount and T Cell-Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells Cancer Res. 2007, 67, 8378-8387
35. Zhong, H.; Han, B.; Tourkova, I. L.; Lokshin, A.; Rosenbloom, A.; Shurin, M. R.; Shurin, G. V. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth Clin. Cancer Res. 2007, 13, 5455-5462
36. Manthey, C. L.; Brandes, M. E.; Perera, P. Y.; Vogel, S. N. Taxol increases steady-state levels of lipopolysaccharide inducible genes and protein tyrosine phosphorylation in murine macrophages J. Immunol. 1992, 149, 2459-2465
37. Lejeune, F.; Lienard, D.; Eggermont, A.; Schraffordt Koops, H.; Rosenkaimer, F.; Gerain, J.; Klaase, J.; Kroon, B.; Vanderveken, J.; Schmitz, P. Rationale for using TNFα and chemotherapy in regional therapy of melanoma J. Cell. Biochem. 1994, 56, 52-61
38. Simon, B. H.; Ando, H. Y.; Gupta, P. K. Circulation Time and Body Distribution of 14C-Labeled Amino-Modified Polystyrene Nanoparticles in Mice J. Pharm. Sci. 1995, 84, 1249-1253
39. Zhang, C.; Qu, G.; Sun, Y.; Wu, X.; Yao, Z.; Guo, Q.; Ding, Q.; Yuan, S.; Shen, Z.; Ping, Q.; Huiping, Z. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel Biomaterials 2008, 29, 1233-1241